Zhejiang CONBA PharmaceuticalLtd Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Guoliang Luo

Chief executive officer

CN¥2.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	0.004%
Management average tenure	no data
Board average tenure	less than a year

Recent management updates

Recent updates

Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

Nov 05

It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Sep 30

Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Sep 12

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Aug 20

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

May 21

CEO

Guoliang Luo (61 yo)

no data

Tenure

CN¥1,978,800

Compensation

Mr. Guoliang Luo serves as President and Director at Zhejiang CONBA Pharmaceutical Co.,Ltd.

Board Members

Name	Position	Tenure	Compensation	Ownership
Guoliang Luo	President & Director	no data	CN¥1.98m	0.0040% CN¥ 459.0k
Ming Chen	VP, CFO & Director	no data	CN¥1.29m	0.00040% CN¥ 46.0k
Jianfeng Ye	VP & Director	less than a year	no data	0.0020% CN¥ 228.9k
Jiqiang Hu	Chairman of the Board	13.6yrs	CN¥2.04m	4.09% CN¥ 470.8m
Shishui Yin	Supervisory Board Chairman	3.2yrs	no data	0.00040% CN¥ 46.0k
Zuojun Dong	Independent Director	no data	CN¥120.00k	no data
En Liu	Independent Director	no data	CN¥120.00k	no data
Yongjiang Wu	Independent Director	no data	CN¥120.00k	no data
Yang Wang	Director	no data	no data	no data
Jiuqin Lu	Independent Director	no data	CN¥120.00k	no data
Yi Jiang	Co-Chairman of Board	less than a year	no data	no data
Qian Jiang	Director	less than a year	no data	no data

0.8yrs

Average Tenure

52yo

Average Age

Experienced Board: 600572's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Zhejiang CONBA PharmaceuticalLtd Management

Management criteria checks 1/4

Key information

Recent management updates

Zhejiang CONBA Pharmaceutical Co.,Ltd., Annual General Meeting, May 10, 2024

Less than half of directors are independent

Recent updates

Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.055 (vs CN¥0.042 in 3Q 2023)

Now 22% overvalued after recent price rise

It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Now 22% overvalued after recent price rise

Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: CN¥0.066 (vs CN¥0.091 in 2Q 2023)

Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) agreed to acquire 20.16% stake in Zhejiang Conba Chinese Traditional Medicine Co., Ltd. from Jiyi (Deqing) Enterprise Management Partnership (Limited Partnership) and Xu Jianhong for approximately CNY 310 million.

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Dividend increased to CN¥0.20

Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly

Zhejiang CONBA Pharmaceutical Co.,Ltd., Annual General Meeting, May 10, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) announces an Equity Buyback for CNY 400 million worth of its shares.

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 17%

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 18, 2023

New minor risk - Share price stability

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.012 loss in 3Q 2021)

Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) signed the equity transfer agreement to acquire Zhejiang Autuokang Pharmaceutical Technology Co., Ltd. from Zhejiang Autuokang Pharmaceutical Group Co., Ltd for CNY 35.58 million.

Second quarter 2022 earnings released: EPS: CN¥0.041 (vs CN¥0.073 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.073 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.02 (vs CN¥0.071 in 1Q 2020)

New 90-day low: CN¥4.30

New 90-day low: CN¥4.48

New 90-day low: CN¥4.82

Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) dropped from FTSE All-World Index (USD)

New 90-day low: CN¥5.15

New 90-day low: CN¥5.21

New 90-day low - CN¥5.39

Zhejiang Traditional Chinese Medicine & Health Industry Group Co., Ltd. completed the acquisition of 20% stake in Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Zhejiang CONBA Group Co., Ltd.

Zhejiang CONBA Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age